Atara Biotherapeutics Inc expected to post a loss of $1.98 a share - Earnings Preview

Atara Biotherapeutics

05/05/2025 12:25

Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Thousand Oaks California-based  company is expected to report a 79.3% decrease in revenue to $5.667 million from $27.36 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Atara Biotherapeutics Inc is for a loss of $1.98 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 3.7% in the last three months. ​

Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $17.00​, above​ its last closing price of $7.82. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-3.76
-3.58
-1.19
Beat
66.7
Sep. 30 2024
-2.11
-1.93
-2.93
Missed
-51.6
Jun. 30 2024
-1.38
-1.56
-3.10
Missed
-98.4​
Mar. 31 2024
-6.17
-6.41
-5.75
Beat
10.3
​​Dec. 31 2023
-7.75
-12.05
-14.00
Missed
-16.2
Sep. 30 2023
-16.57
-16.55
-16.50
Beat
0.3​
Jun. 30 2023
-16.58
-16.81
-17.00
Missed
-1.1
Mar. 31 2023
-9.39
-9.79
-18.00
Missed
-83.8

This summary was machine generated May 5 at 11:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)